SCHEMBL5872360

SCHEMBL5872360

CCCCCC1C(=O)CCC1C(C(=O)O)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGER2 P43116 9/20 0.45
▸ PTGER3 P43115 4/20 0.45
▸ PTGER4 P35408 3/20 0.45
▸ TSHR P16473 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CYP1A2 P05177 2/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ NR4A2 P43354 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ ABCC3 O15438 1/20 0.36
▸ ABCC4 O15439 1/20 0.36
▸ RARB P10826 1/20 0.36
▸ RARG P13631 1/20 0.36
▸ DRD1 P21728 1/20 0.36
▸ PTGIR P43119 1/20 0.36
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11417780 0.89 PTGER2 (0.43) PTGER2PTGER3PTGER4TSHRHTT
SCHEMBL2120762 0.87 PTGER2 (0.44) PTGER2PTGER3PTGER4TSHRHTT
SCHEMBL453839 0.87 PTGER2 (0.44) PTGER2PTGER3PTGER4TSHRHTT
SCHEMBL28945563 0.87 PTGER2 (0.44) PTGER2PTGER3PTGER4TSHRHTT
SCHEMBL22125297 0.85 PTGER2 (0.46) PTGER2PTGER3PTGER4TSHRHTT
SCHEMBL22125277 0.85 PTGER2 (0.43) PTGER2PTGER3PTGER4TSHRHTT
SCHEMBL5872496 0.84 PTGER2 (0.45) PTGER2PTGER3PTGER4TSHRHTT
SCHEMBL9015808 0.84 PTGER2 (0.45) PTGER2PTGER3PTGER4TSHRHTT
SCHEMBL22125385 0.82 HTT (0.42) PTGER2PTGER3PTGER4TSHRHTT
SCHEMBL11830401 0.81 PTGER2 (0.46) PTGER2PTGER3PTGER4TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114349640-B Synthesis method of methyl dihydrojasmonate or intermediate thereof and catalyst used in synthesis method 山东新和成药业有限公司 2024-03-22 — — CN disclosed
EP-1498407-B1 Method of producing acetate derivative KAO CORP (JP) 2012-09-05 — — EP disclosed
US-7078559-B2 Method of producing acetate derivative KAO CORPORATION (JP) 2006-07-18 — — US disclosed
US-20050014968-A1 Method of producing acetate derivative KAO CORPORATION (JP) 2005-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014968-A1 Method of producing acetate derivative DECR1, CYP51A1, DECR2 PTGER2 1768/4885PTGER3 1210/4885PTGER4 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback